Latest News

The proportion of breast cancer potentially flagged by three different AI algorithms 10 years prior to diagnosis ranged between 12.7 to 17 percent, according to newly published retrospective research.

Use of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide led to a > 30 percent reduction in liver fat content in nearly 85 percent of obese patients with at-risk MASLD, according to MRI findings in new phase 3 research.

Are you on the right path to financial independence and retiring early?

Catch up on a variety of new FDA clearances in radiology from the past week.

Catch up on the top radiology content of the past week.

While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.

The MIM Contour ProtegeAI+ 2.0 software reportedly offers new AI-powered contouring models for brain MRIs and pelvic CTs.

In comparison to short-axial field of view PET/CT scanners, a total body PET/CT imaging platform with a long axis field of view detected more lesions in 68 percent of patients while reducing scan times by 83 percent, according to new research presented at the SNMMI conference.

In a recent interview, Phillip Kuo, MD, discussed new comparative multicenter prospective research, presented at the SNMMI conference, examining the urinary radioactivity of two PSMA PET radiotracers 18F-piflufolastat and 18F-flotufolastat.

Preliminary research findings, presented at the SNMMI conference, suggest that the alpha-emitting radioconjugate ATNM-400 may be a viable alternative for treating PCa that is resistant to androgen receptor pathway inhibitors (ARPIs).

Noting the potential for workload efficiencies in interpreting screening digital breast tomosynthesis (DBT) images, researchers found the use of slab reconstruction technology improved specificity without any impact on sensitivity or cancer detection rate.

Reportedly trained on thousands of cardiac ultrasound images, the Ejection Fraction (EF) AI tool provides automated measurement of left ventricular ejection fraction (LVEF) in seconds.

The AI-powered Elevate Plus reportedly facilitates standardization of routine ultrasound, improves scan time and bolsters image quality.